| Alex G Ortega Loayza, MD | |
|
3303 Sw Bond Ave, Mailcode: Ch16d, Portland, OR 97239-4501 | |
| (503) 494-3376 | |
| (503) 346-8106 |
| Full Name | Alex G Ortega Loayza |
|---|---|
| Gender | Male |
| Speciality | Dermatology |
| Experience | 20 Years |
| Location | 3303 Sw Bond Ave, Portland, Oregon |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1790946903 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207N00000X | Dermatology | 0101255893 (Virginia) | Secondary |
| 207N00000X | Dermatology | MD175789 (Oregon) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Ohsu Hospital And Clinics | Portland, OR | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Oregon Health And Sciences University/university Medical Group | 4880760107 | 1485 |
News Archive
PTC Therapeutics, Inc. is pleased to announce five recipients of its first-ever global awards program, the STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment), designed to aid nonprofit organizations that are committed to serving the Duchenne muscular dystrophy (DMD) community.
Patients who survive a brief cardiac arrest and who appear neurologically intact should nonetheless receive a detailed neuropsychological assessment before being discharged, suggests a joint study by researchers at Baycrest's Rotman Research Institute and Israel's Rambam Medical Center.
A study led by researchers at the University of California, San Diego School of Medicine shines a new light on molecular tools our cells use to govern regulated gene expression. The study was published on line in advance of print November 10 in the journal Nature Structural and Molecular Biology.
Neurologix, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for intellectual property central to the company's approach to the treatment of epilepsy. The patent allowance specifically refers to Neurologix's patent application, "Methods and Compositions for the Treatment of Neurological Disease," which covers the treatment of seizures associated with temporal lobe epilepsy by direct administration into the brain's temporal lobe of an AAV vector encoding Neuropeptide Y (NPY).
New research led by UC Health cardiologists shows that while short-term worsening kidney function is frequent among patients with heart failure, these patients also have better outcomes than those who have persistent kidney failure
› Verified 8 days ago
| Entity Name | University Professional Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1376709535 PECOS PAC ID: 4880760107 Enrollment ID: O20080910000013 |
News Archive
PTC Therapeutics, Inc. is pleased to announce five recipients of its first-ever global awards program, the STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment), designed to aid nonprofit organizations that are committed to serving the Duchenne muscular dystrophy (DMD) community.
Patients who survive a brief cardiac arrest and who appear neurologically intact should nonetheless receive a detailed neuropsychological assessment before being discharged, suggests a joint study by researchers at Baycrest's Rotman Research Institute and Israel's Rambam Medical Center.
A study led by researchers at the University of California, San Diego School of Medicine shines a new light on molecular tools our cells use to govern regulated gene expression. The study was published on line in advance of print November 10 in the journal Nature Structural and Molecular Biology.
Neurologix, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for intellectual property central to the company's approach to the treatment of epilepsy. The patent allowance specifically refers to Neurologix's patent application, "Methods and Compositions for the Treatment of Neurological Disease," which covers the treatment of seizures associated with temporal lobe epilepsy by direct administration into the brain's temporal lobe of an AAV vector encoding Neuropeptide Y (NPY).
New research led by UC Health cardiologists shows that while short-term worsening kidney function is frequent among patients with heart failure, these patients also have better outcomes than those who have persistent kidney failure
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Alex G Ortega Loayza, MD 3303 Sw Bond Ave, Mailcode: Ch16d, Portland, OR 97239-4501 Ph: (503) 494-3376 | Alex G Ortega Loayza, MD 3303 Sw Bond Ave, Mailcode: Ch16d, Portland, OR 97239-4501 Ph: (503) 494-3376 |
News Archive
PTC Therapeutics, Inc. is pleased to announce five recipients of its first-ever global awards program, the STRIVE Awards (Strategies to Realize Innovation, Vision and Empowerment), designed to aid nonprofit organizations that are committed to serving the Duchenne muscular dystrophy (DMD) community.
Patients who survive a brief cardiac arrest and who appear neurologically intact should nonetheless receive a detailed neuropsychological assessment before being discharged, suggests a joint study by researchers at Baycrest's Rotman Research Institute and Israel's Rambam Medical Center.
A study led by researchers at the University of California, San Diego School of Medicine shines a new light on molecular tools our cells use to govern regulated gene expression. The study was published on line in advance of print November 10 in the journal Nature Structural and Molecular Biology.
Neurologix, Inc. today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office for intellectual property central to the company's approach to the treatment of epilepsy. The patent allowance specifically refers to Neurologix's patent application, "Methods and Compositions for the Treatment of Neurological Disease," which covers the treatment of seizures associated with temporal lobe epilepsy by direct administration into the brain's temporal lobe of an AAV vector encoding Neuropeptide Y (NPY).
New research led by UC Health cardiologists shows that while short-term worsening kidney function is frequent among patients with heart failure, these patients also have better outcomes than those who have persistent kidney failure
› Verified 8 days ago
Dr. Alison Marie Small, M.D. Dermatology Medicare: Medicare Enrolled Practice Location: 3303 Sw Bond Ave, Portland, OR 97239 Phone: 503-418-3376 | |
Milie Fang, DO Dermatology Medicare: Not Enrolled in Medicare Practice Location: 3303 S Bond Ave Dept, Portland, OR 97239 Phone: 503-494-1375 | |
Bert G Tavelli, MD Dermatology Medicare: Accepting Medicare Assignments Practice Location: 2525 Nw Lovejoy St Ste 400, Portland, OR 97210 Phone: 503-223-1933 Fax: 503-223-1947 | |
Natasha Fewkes Carter, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 4914 Sw 1st Ave, Portland, OR 97239 Phone: 310-701-8274 | |
Dr. Samuel Fritz Bremmer, M.D. Dermatology Medicare: Accepting Medicare Assignments Practice Location: 3181 Sw Sam Jackson Park Rd, Portland, OR 97239 Phone: 503-494-8211 | |
Oluwadamilare Olalekan Ajayi, MD Dermatology Medicare: Medicare Enrolled Practice Location: 3303 S Bond Ave, Portland, OR 97239 Phone: 503-418-3376 Fax: 503-494-6968 | |
Diane Romayne Baker, MD Dermatology Medicare: Not Enrolled in Medicare Practice Location: 9495 Sw Locust St Ste A&e, Portland, OR 97223 Phone: 503-471-0500 Fax: 503-471-0504 |